Systemic Sclerosis
Systemic sclerosis (SSc) is a complex, chronic autoimmune disease that affects many organs. It is defined by three intertwined processes: damage to small blood vessels and their endothelium, abnormal activation of the immune system, and progressive, widespread fibrosis of the skin and internal organs. The disease begins when an initial trigger injures small vessels, releasing proinflammatory cytokines and growth factors such as TGF-beta and PDGF. These signals turn fibroblasts into myofibroblasts, which overproduce and deposit extracellular matrix, especially type I and III collagen. The result is thick, hard skin and fibrosis of the lungs, heart, kidneys and digestive tract.
At Haute-Derma, our approach to systemic sclerosis centers on early intervention and thorough protection of the microcirculation. Tight, thickened skin affects more than appearance and movement; it is often a window onto how severely the internal organs are involved. Our aim is to interrupt the fibrotic process early, protect the peripheral blood vessels and coordinate care across specialties to improve your long-term outlook.
Our Approach to Treating Systemic Sclerosis
Systemic sclerosis can progress quietly yet leave serious lasting damage, so Haute-Derma follows a strategy of "protect the vessels, halt the fibrosis":
- Accurate subtyping: We clearly distinguish limited cutaneous SSc (lcSSc: skin changes confined to below the elbows and knees, with long-standing Raynaud phenomenon) from diffuse cutaneous SSc (dcSSc: skin changes spreading quickly to the upper arms, thighs and trunk, with a risk of early organ fibrosis), so treatment can be targeted.
- Proactive screening for lung and kidney complications: Working closely with pulmonologists and cardiologists, we arrange regular lung function tests and low-dose chest CT to catch interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) early. These are the two leading causes of death in SSc.
- Combined rehabilitation and tissue-softening therapy: Physical therapy, heat therapy and topical biologically active agents help maintain joint range of motion and limit tightening of the skin over the fingers.
How We Diagnose Systemic Sclerosis at Haute-Derma
At Haute-Derma, we confirm systemic sclerosis using the American College of Rheumatology / European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria:
Assessing Characteristic Clinical Signs
- Sclerodactyly: the skin of the fingers becomes thick, tight and shiny and loses its creases, so the fingers tend to curl into a claw-like position.
- Raynaud phenomenon: spasm of the finger or toe arteries in response to cold or stress, with three distinct color phases: white (loss of blood flow) → blue (pooled, deoxygenated blood) → red (blood flow returning).
- Facial changes: taut skin with loss of natural expression lines, thin and narrowed lips (a small mouth that cannot open wide) and radial furrows around the mouth.
- Superficial vascular changes: telangiectasias on the face and palms, and painful fingertip ulcers (digital ulcers) and pitted scars.
Immunologic and Microcirculation Testing
- Nailfold capillaroscopy: a specialized technique that uses magnification to view the tiny vessels of the nailfold directly. It can reveal early SSc-specific changes, including giant capillaries, avascular areas and microhemorrhages, allowing diagnosis even before symptoms are obvious.
- Skin biopsy: a sample taken from hardened skin shows a markedly thickened dermis made up of coarse, tightly packed collagen bundles running parallel to the surface, with shrinkage of skin appendages such as sweat and sebaceous glands.
- Scleroderma antibody panel: identifies the key autoantibodies:
- Anti-centromere (ACA): usually positive in limited SSc; organ fibrosis is less likely, but there is a risk of late pulmonary hypertension.
- Anti-Scl-70 (anti-topoisomerase I): usually positive in diffuse SSc and closely linked to progressive interstitial lung fibrosis.
- Anti-RNA polymerase III: associated with very rapidly progressing skin disease and a risk of scleroderma renal crisis.
How Systemic Sclerosis Is Treated at Haute-Derma
No single drug treats every feature of systemic sclerosis, so our protocols target the specific organs involved:
- Managing Raynaud phenomenon and digital ulcers: calcium channel blockers (such as nifedipine or amlodipine) or phosphodiesterase-5 inhibitors (sildenafil) widen the vessels, improve blood flow to the extremities, help fingertip ulcers heal and relieve pain.
- Slowing interstitial lung disease (SSc-ILD): for patients whose CT shows progressive interstitial lung disease, immunosuppressants such as mycophenolate mofetil (MMF) or intravenous cyclophosphamide are used to slow the decline in lung function. The targeted antifibrotic nintedanib may be added to slow fibrosis of the air sacs.
- Preventing and treating renal crisis: blood pressure is monitored closely. At the first signs of scleroderma renal crisis (a sudden surge in blood pressure with acute kidney failure), ACE inhibitors such as captopril or enalapril are started urgently. They are the cornerstone of treatment and have been shown to markedly improve kidney survival and overall survival in this complication.
- Immunomodulators and cautious corticosteroid use: methotrexate is used early in diffuse disease to reduce skin hardening and improve joint symptoms. Oral systemic corticosteroids are always weighed very carefully, because high doses are a leading known trigger of acute renal crisis.
- Topical care and rehabilitation: intensive moisturizing ointments containing urea or hyaluronic acid, combined with massage, help soften the tissue. Patients learn daily finger exercises and facial stretches to counter the pull of fibrotic tissue.
